Chronic Lymphocytic Leukemia (CLL) is the most common adult leukemia of in the United States. The tissue microenvironment, specifically the lymph nodes (LN), influences the biological and clinical behavior of CLL cells. Gene expression profiling of CLL cells from peripheral blood (PB), bone marrow (BM) and LNs, revealed Cav-1 as one of the candidate genes which might be involved in the pathogenesis of CLL. We have previously shown that the knock-down of Cav-1 in primary CLL cells showed a significant decrease in cell migration and immune synapse formation. However the precise role of Cav-1 in the CLL initiation and progression in vivo is not known. Therefore, we decreased the expression of cav-1 in vivo by breeding Eμ-TCL1 with cav-1 knockout mice. We observed a significant decrease in number of CLL cells the rate of proliferation of CLL cells in spleen, liver and BM from Eμ-TCL1-Cav1(-/+) and Eμ-TCL1-Cav1(-/-) compared with Eμ-TCL1 mice. In addition there was a significant increase in survival of Eμ-TCL1-Cav1(-/+) and Eμ-TCL1-Cav1(-/-) compared with Eμ-TCL1 mice. Mechanistically, we observed a decrease in MAPK-Erk signaling measured by p-Erk levels in Eμ-TCL1-Cav1(-/+) mice when compared with Eμ-TCL1-Cav(wt/wt). Together these results demonstrated that decreased cav-1 in Eμ-TCL1 mice significantly delayed the onset of CLL and decreased leukemic progression by inhibiting MAPK-Erk signaling, thus suggesting a role for cav-1 in the proliferation and progression of CLL.